Tau immunotherapies have also been proposed based on the preclinical studies43–45, and they quickly moved into clinical trials45–48 as disease-modifying treatments of dementia associated with various Tauopathies, including AD. The gene discussed is MAPT; the disease is Alzheimer disease.